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Comparison of corifollitropin alfa and daily recombinant 
follicle-stimulating hormone in poor responder patients 
undergoing in vitro fertilization cycles
Düşük over yanıtlı hasta grubunda corifollitropin alfa ve 
rekombinant folikül uyarıcı hormonun in vitro fertilizasyon 
sikluslarında karşılaştırılması
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Öz
Amaç: Bu çalışmanın amacı düşük over yanıtlı hasta grubunda antagonist sikluslarda korifollitropin alfa (CFA) ve rekombinant folikül stimülant hormonun 
(rFSH) etkinliğini karşılaştırmaktı.
Gereç ve Yöntemler: Çalışma İzmir Medical Park Hastanesi İn Vitro Fertilizasyonu Merkezi’nde Kasım 2014 ile Kasım 2016 tarihleri arasında düşük over 
yanıtlı toplam 214 hastanın kayıtlarından retrospektif olarak yapıldı. Otuz sekiz hastaya CFA (grup 1), 176 hastaya (grup 2) rFSH kulanılarak kontrollü 
ovaryan stimülasyon yapıldı.
Bulgular: Yaş, vücut kitle indeksi, anti-müllerian hormon düzeyi, infertilite süresi, indüksiyon süresi ve antral follikül sayısı her iki grupta aynıydı. Aspire 
edilen toplam oosit sayısı, matür oosit oranı, fertilizasyon oranı, implantasyon oranı ve klinik gebelik oranı açısından her iki grup arasında fark gözlenmedi. 
İmplantasyon oranı grup 1’de 9/38 (%23,6) ve grup 2’de 42/176 (%23,8) iken; klinik gebelik oranı sırasıyle grup 1’de %16,3 ve  grup 2’de %17,2 idi.
Sonuç: Düşük over yanıtlı hasta gruplarında yapılan antagonist sikluslarda CFA ve rFSH kullanımının oosit sayısı, fertilizasyon oranı, implantasyon oranı 
ve klinik gebelik oranı arasında fark yoktur.
Anahtar Kelimeler: Korifollitropin alfa, yumurtalık rezervinin azalması, gonadotropin salgılatıcı hormon antagonisti, in vitro fertilizasyonu, düşük over 
yanıtlı
Abstract
Objective: The aim of this study was to compare the effect of corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) in poor-
responder patients undergoing antagonist cycles.
Materials and Methods: The study was a retrospective analysis of the treatment results of 214 poor responder patients who had been admitted to the In 
Vitro Fertilization Unit of İzmir Medical Park Hospital between November 2014 and November 2016. Intracytoplasmic sperm injections were performed 
in 38 patients (group 1) with CFA, and the remaining 176 (group 2) with rFSH for controlled ovarian hyperstimulation.
Results: The age, body mass index, anti-müllerian hormone level, duration of infertility, duration of induction and antral follicle number were similar in 
the two groups. There was no difference in the total aspirated oocyte counts, mature oocyte ratio, fertilization rate, implantation rate, and clinical pregnancy 
rates between the two groups. The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2, whereas the clinical pregnancy rates 
were 16.3% and 17.2%, respectively.
Conclusion: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the 
antagonist cycles in poor-responder patients.
Keywords: Corifollitropin alfa, diminished ovarian reserve, gonadotropin-releasing hormone antagonist, in vitro fertilization, poor responder
PRECIS: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA 
or rFSH use in the antagonist cycles in poor-responder patients. 
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Introduction
Corifollitropin alfa (CFA) is a new gonadotropin analogue with 
follicle-stimulating hormone (FSH) activity, which is effective 
for 7 days at the beginning and continuation of multi-follicular 
development(1). This FSH analogue is a recombinant molecule 
that contains the carboxy terminal peptide structure of the 
human FSH beta subunit, but does not exhibit luteinizing 
hormone (LH) activity that affects only FSH receptors(1,2). The 
greatest advantage of this molecule is the half-life of about 68 
hours(3). The pharmacodynamic properties of this molecule are 
that the serum concentration reaches the peak level (T-max) in 
a short time and reaches the maximum concentration (C-max) 
after 25-45 hours of injection(4). There are no adverse effects 
or complications associated with this drug, which is well 
tolerated by patients(5). The treatment of patients with low over-
exposure has been the main topic of many randomized studies 
in past years. Different treatment regimens have been applied to 
increase over-response and pregnancy rates. Decreasing oocyte 
quality and decreasing over-reserve are closely related to female 
age(6-8). The European Society of Human Reproduction and 
Embryology developed a new definition called Bologna criteria 
in 2011 for the poor-response patient group(9)). These criteria 
are: 1) older age of women (40 years) or other existing factors 
causing diminished ovarian reserve (DOR); 2) less oocyte 
counts in treatments taken in previous treatments (3 oocytes); 
3) disorder in over reserve tests [antral follicles <5-7 or anti-
müllerian hormone (AMH) <0.5-1.1 ng/mL]. Two of these 
criteria will cause the patient to have a diagnosis of DOR(9).
Materials and Methods
This study was the result of a retrospective study of 214 patients 
who were diagnosed as having DOR according to the Bologna 
criteria at the in vitro fertilization (IVF) Unit of İzmir Medical 
Park Hospital between November 2014 and November 2016. 
Ethics committee approval was obtained from İzmir University 
Ethics Committee (approval number: 012742) before the study 
commencement. Informed consent was obtained from all of the 
study participants. The inclusion criteria were: being aged <45 
years old, regular menstrual cycles (24-35 days), body mass 
index of 18-30 kg/m2, absence of any endocrine pathology, 
no severe male factor (total progressive motile sperm count 1 
million/mL (Table 1). Thirty-eight patients were treated with 
single-dose subcutaneous injection of 150 µg CFA (Elonva, NV 
Organon, Oss, Netherlands) on the second or third day of the 
cycle as the first day of controlled ovarian hyperstimulation 
(COH). On the seventh day of treatment, 300 IU of highly 
purified human menopausal gonadotrophin (Merional, IBSA, 
Switzerland or Menopur, Ferring, Turkey) were administered, 
similar to the protocol of Polyzos and Devroey(6), subcutaneously 
per day to each patient (group 1). The remaining 176 patients 
were treated with 300 IU follitropin alpha (Gonal-f; Merck, 
Switzerland) or follitropin beta (Puregon; NV Organon, Oss, 
Netherlands) subcutaneously on the second or third day of 
the cycle (group 2). In both groups, 0.25 mg gonadotropin-
releasing hormone (GnRH) ganirelix (Orgalutran; NV 
Organon, Oss, Netherlands) or cetrorelix (Cetrotide; Merck, 
Switzerland) was given daily until the day of human chorionic 
gonadotropin (hCG) to prevent premature luteinization when 
the follicle diameter was 13 mm or more. When the leading 
follicle was 18 mm, 250 µg recombinant hCG (Ovitrelle; 
Merck, Switzerland) was administered subcutaneously for the 
final maturation of the oocyte. Thirty-five hours later, under 
general anesthesia, transvaginal ultrasound-guided oocyte 
pick-up was performed. Intracytoplasmic sperm injections was 
applied to all patients. All embryos were cultured for three days 
in vitro and then transferred in the presence of transabdominal 
ultrasonographic guidance. Four hundred milligrams per day 
of micronized progesterone (Progestin capsules 200 mg, Koçak 
Farma, İstanbul, Turkey) and 90 mg progesterone gel (Crinone 
gel, Merck, Switzerland) were applied vaginally for luteal phase 
support. On the second day of the cycle, serum estradiol, LH, 
and FSH, and on the day of hCG treatment, estradiol, LH, and 
progesterone values  were recorded. On the second, seventh, 
and hCG days of the cycle, follicle evaluation was performed 
using transvaginal ultrasonography. Twelve days after the 
embryo transfer, a beta-hCG test was performed. Transvaginal 
ultrasonographic evaluation was performed for fetal heart beat 
two weeks after a finding a positive hCG test.
Statistical Analysis
The Statistical Package for the Social Sciences program (SPSS 
20) [International Business Machines (IBM) Corp. released 
2011. IBM SPSS Statistics for Windows, version 20.0, Armonk, 
NY: IBM Corp.] was used to evaluate the data. Variables mean 
+ standard deviation and median (minimum-maximum) 
percentage and frequency values  were used. The homogeneity 
of the variances from the preconditions of the parametric tests 
was checked using the Levene test. The assumption of normality 
was examined using the Shapiro-Wilk test. The differences 
between the two groups were evaluated using Student’s t-test 
Table 1. Demographic characteristics of patients
Grup 1 Grup 2 p
Patient number 25 119
Age (year) 39.2 38.1 0.954
BMI (kg/m2) 26.1 25.4 0.687
Duration of infertility (year) 5.3 5.7 0.545
Duration of induction (day) 10.5 10.3 0.998
Number of antral follicule 5.1 5.2 0.997
Endometrial thickness (hCG day) 8.1 8.3 0.995
AMH (ng/dL) 0.81 0.69 0.412
Progesteron (hCG day µg/L) 1.32 1.45 0.124
BMI: Body mass index, AMH: Anti-müllerian hormone, hcG: Human chorionic 
gonadotropin
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when parametric test prerequisites were provided, and the 
Mann-Whitney U test was used when the conditions were 
not met. Categorical data were analyzed using the maximum 
likelihood and chi-square tests. In cases where the expected 
frequencies were less than 20%, the Monte Carlo Simulation 
Method was used including these frequencies in the analysis. 
For the significance level of the tests, p<0.01 was accepted.
Results
CFA (group 1) was applied to 38 of 214 patients with DOR, as 
diagnosed according to the Bologna criteria, and recombinant 
FSH and antagonist protocol (group 2) treatment was applied 
to the remaining 176 patients. It was not possible to retrieve 
any oocytes in 13 (34.2%) patients in group 1 and 57 (32%) 
patients in group 2; therefore, these cycle were cancelled 
(p=0.718). The mean number of oocytes collected in group 1 
with 25 patients with at least one oocyte was 3.2, and in group 
2 with 119 patients it was 3.4 (p=0.879). The mean number 
of mature oocytes metaphase 2 was 1.8 in group 1 and 1.6 in 
group 2 (p=0.745). The duration of stimulation was 10.52 days 
in group 1 and 10.34 days in group 2 (p=0.894). The mean 
number of transferred embryos was 1.6 in group 1, whereas 
this value was 1.5 in group 2 (p=0.478). The implantation rate 
was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 
2 (p=0.578), and the clinical pregnancy rate was 16.3% and 
17.2%, respectively (p=0.622). Multiple pregnancy and drug 
adverse effects were not observed in any patients (Table 2).
Discussion
Since 2008, there have been different results in a limited 
number of studies on single-dose CFA administration. In 2008, 
Devroey et al.(10) wrote the first study about CFA. The authors 
suggested that a single injection of corifollitropin alfa induced 
a dose-related increase in multifollicular development and in 
the number of retrieved oocytes(11). Devroey et al.(10) postulated 
that CFA was a novel and effective treatment option for potential 
normal-responder patients undergoing ovarian stimulation with 
GnRH antagonist co-treatment for IVF resulting in ongoing 
pregnancy rates equal to that achieved with daily rFSH. 
Mahmoud Youssef et al.(12) published a meta-analysis in 2012. 
They included four randomized trials involving 2326 women. 
There was no evidence of a statistically significant difference 
in ongoing pregnancy rates for CFA versus rFSH(12). Boostanfar 
et al.(13) designed a large comparative randomized double-
blind trial that confirmed the non-inferiority of pregnancy 
rates for CFA compared with recombinant FSH in a GnRH 
antagonist COH protocol in advance-age patients undergoing 
IVF. CFA was proven noninferior to daily rFSH with respect to 
cardiopulmonary resuscitations, number of oocytes retrieved, 
and live birth rates, and the drug was generally well tolerated(13). 
Another study was designed by Polyzos et al.(14) with poor 
ovarian responders. In this study, the Bologna criteria were 
used to enroll the patients. The protocol with CFA in this 
group of patients resulted in low poor responder (PR) similar 
to the conventional short agonist protocol(14). Revelli et al.(15) 
demonstrated that starting CFA on day 4 of the cycle resulted in 
comparable PR with significantly less injections and a similar risk 
of Ovarian Hyperstimulation syndrome (OHSS)(15). On the other 
hand Oehninger reported that, in women aged 35 to 42 years, 
the prediction of ovarian response to CFA treatment was related 
with AMH, AFC, and age at the start of stimulation for in both 
high and PR patients(16). In addition, basal FSH values for high 
ovarian response and menstrual cycle length for poor ovarian 
response were prognostic. In a meta-analysis consisting of 2138 
women who were randomized to receive corifollitropin alfa 
and 1788 who were randomized to receive daily rFSH, Fensore 
et al.(17) emphasized that the risk of cycle cancellation due to 
overstimulation was significantly higher in the CFA group. On 
the other hand, the incidence of OHSS was comparable between 
patients receiving long-lasting or daily rFSH. Accordingly, they 
suggested that CFA resulted in a higher number of metaphase 2 
oocytes collected and a higher number of cycles cancelled due to 
overstimulation; therefore, CFA should be cautiously considered 
in women with the potential of being hyper-responders. In 
view of this meta-analysis, one can consider using CFA more 
effectively for patients with DOR, but to date, the results have 
not been consistent. In a retrospective study, Polyzos et al.(14) 
used HP-hMG as an additional gonadotropin in poor-responder 
patients according to the Bologna criteria. They achieved a 
very reasonable ongoing pregnancy rate (28%) in patients aged 
below 40 years, whereas no pregnancies occurred in patients 
aged over 40 years.
Study Limitations
The retrospective design is the major limitation of our study. 
Therefore, prospective randomized studies are also necessary 
about this subject. 
Table 2. Over response, embryo results and pregnancy rates
Grup 1 Grup 2 p
Patient Number 38 176
Number of cycles cancelled 13 (34.2%) 57 (32%) 0.72
Number of taken oocytes 3.2 3.4 0.88
MII Number 1.8 1.6 0.75
2PN Number 1.5 1.4 0.99
Emb Grade
         Grade 1-2 11 (44%) 48 (40.3%) 0.74
         Grade 3-4 14 (56%) 71 (59.7%) 0.74
Transferred embriyo number 1.6 1.5 0.48
Pozitive hCG 9 (23.6%) 42 (23%) 0.58
Clinical pregnancy 16.3% 17.2% 0.64
Emb: Endometrial biopsy, 2PN: Two-pro-nucleii, hcG: Human chorionic gonadotropin 
MII: Metaphase II
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Conclusion
CFA is a long-acting novel gonadotropin for COH. In our 
study, we used a similar protocol to Polyzos et al.(14) who found 
considerably high PR in patients with DOR, particularly in 
the younger age group. Unfortunately, we could not show any 
difference between the two different COH modalities. Although 
the CFA treatment was well accepted by the patients, the high 
cost of the medication was a limiting concern. As far as we 
know, this is the first study to report the use of CFA in patients 
with DOR from our country. 
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